Efficacy and immunogenicity of a veterinary vaccine candidate against tick-borne encephalitis in dogs

Warning

This publication doesn't include Faculty of Education. It includes Faculty of Science. Official publication website can be found on muni.cz.
Authors

SALÁT Jiří HUNADY Milan SVOBODA Pavel STŘELCOVÁ Lucie STRAKOVÁ Petra FOŘTOVÁ Andrea PALUS Martin RŮŽEK Daniel

Year of publication 2023
Type Article in Periodical
Magazine / Source Vaccine
MU Faculty or unit

Faculty of Science

Citation
Web https://doi.org/10.1016/j.vaccine.2023.09.019
Doi http://dx.doi.org/10.1016/j.vaccine.2023.09.019
Keywords Tick-borne encephalitis; Vaccine; Dogs
Description Tick-borne encephalitis (TBE) is a severe neuroinfection of humans. Dogs are also commonly infected with tick-borne encephalitis virus (TBEV). These infections are usually asymptomatic, but sometimes show clinical signs similar to those seen in humans and can be fatal. To date, there is no TBEV vaccine available for use in dogs. To address this need, a TBEV vaccine candidate for dogs based on inactivated whole virus antigen was developed. The safety, immunogenicity, and efficacy of the vaccine candidate were tested in mice as the preclinical model and in dogs as the target organism. The vaccine was well tolerated in both species and elicited the production of specific anti-TBEV antibodies with virus neutralising activity. Vaccination of mice provided complete protection against the development of fatal TBE. Immunisation of dogs prevented the development of viremia after challenge infection. Therefore, the developed vaccine candidate is promising to protect dogs from severe TBEV infections.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.